Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
By D. Heng, W. Xie, M. Regan, M. Warren, A. Golshayan, C. Sahi, B. Eigl, J. Ruether, T. Cheng, S. North and 10 more. Journal of Clinical Oncology, 2009
1,988 citations recorded by the source corpus.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/fa444ae19f98773372171815bef715351d0a9dd9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, result): “A recent evaluation of this model in second-line treatment underscored its predictive value in previously treated mRCC [23] (Table 5).”
- Renal cell carcinoma (2017, result): “A recent evaluation of this model in second-line treatment underscored its predictive value in previously treated mRCC [23] (Table 5).”
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019, methodology): “IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year”
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018, neutral): “Fatigue 202 (37) 23 (4) 264 (49) 49 (9)”
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, result): “A recent evaluation of this model in second-line treatment underscored its predictive value in previously treated mRCC [23] (Table 5).”